John H. Sampson

Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma.

Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system.

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.

Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion.

Intracanalicular meningioma mimicking vestibular schwannoma.

Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).

Phase II trial of temozolomide in patients with progressive low-grade glioma.

Viruses in the treatment of brain tumors.

Clinical immunotherapy for brain tumors.

The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.

Adoptive immunotherapy for malignant glioma.

Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.

Phase II trial of gefitinib in recurrent glioblastoma.

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.

Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer.

Immunotherapy of surgical malignancies.

Microvascular decompression for glossopharyngeal neuralgia: long-term effectiveness and complication avoidance.

Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.

Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.

Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.

Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus.

Poliovirus receptor CD155-targeted oncolysis of glioma.

Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study.

Surgical management of petroclival meningiomas: defining resection goals based on risk of neurological morbidity and tumor recurrence rates in 137 patients.

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.

Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus.

Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

Convection-enhanced delivery of therapeutics for brain disease, and its optimization.

Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies.

Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies.

Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.

Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.

Preoperative functional MR imaging localization of language and motor areas: effect on therapeutic decision making in patients with potentially resectable brain tumors.

Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin.

Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity.

Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers.

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.

Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning.

Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin.

Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.

Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.

Viruses in the treatment of malignant glioma.

Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions.

EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells.

Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma.

Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.

Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.

Cholesterol granuloma of the lateral ventricle. Case report.

Immunotherapy of malignant brain tumors.

Cryptococcal meningitis in patients with glioma: a report of two cases.

Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.

Selective modification of antigen-specific T cells by RNA electroporation.

Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.

Combating immunosuppression in glioma.

Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.

A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells.

Stereotactic body radiotherapy for lesions of the spine and paraspinal regions.

Proteomic and immunologic analyses of brain tumor exosomes.

Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.

Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.

IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era.

Paraganglioma of the head and neck: long-term local control with radiotherapy.

A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas.

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.

Toward effective immunotherapy for the treatment of malignant brain tumors.

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.

The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.

Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.

EGFRvIII-targeted vaccination therapy of malignant glioma.

An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.

Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1.

Clinical applications of a peptide-based vaccine for glioblastoma.

The role of tregs in glioma-mediated immunosuppression: potential target for intervention.

Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration.

Poor drug distribution as a possible explanation for the results of the PRECISE trial.

Long-term safety of combined intracerebral delivery of free gadolinium and targeted chemotherapeutic agent PRX321.

The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor.

Immunotherapy approaches for malignant glioma from 2007 to 2009.

Stereotactic radiosurgery in the treatment of a dural carotid-cavernous fistula.

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.

Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study.

Low-grade glioma.

A comprehensive outlook on intracerebral therapy of malignant gliomas.

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.

Resection of vestibular schwannomas.

A novel method for volumetric MRI response assessment of enhancing brain tumors.

Clinical trial end points for high-grade glioma: the evolving landscape.

Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans.

Bispecific antibodies engage T cells for antitumor immunotherapy.

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.

Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.

Epidemiology.

The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.

Our failure to advance new treatments for glioma to market.

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.

Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.

Convection-enhanced delivery.

Is cytomegalovirus a therapeutic target in glioblastoma?

Disparities in care.

Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.

Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.

Avastin: more questions than answers. . .

Clinical data simplified.

Monitoring radiographic brain tumor progression.

Imaging of convection enhanced delivery of toxins in humans.

Immunotherapy with tumor vaccines for the treatment of malignant gliomas.

Convection enhanced delivery of macromolecules for brain tumors.

A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.

Toxin-based targeted therapy for malignant brain tumors.

Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.

Resection and survival.

The use of motor mapping to aid resection of eloquent gliomas.

Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme.

Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.

Editorial: Convection-enhanced delivery.

Enzyme redesign guided by cancer-derived IDH1 mutations.

Contemporary surgical management of vestibular schwannomas: analysis of complications and lessons learned over the past decade.

Subarachnoid hemorrhage trials.

Regulatory T cells move in when gliomas say "I Do".

The limitations of imaging response criteria.

Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.

Thickness of subcutaneous fat as a risk factor for infection in cervical spine fusion surgery.

Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.

Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.

BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.

Radiotherapy and radiosurgery for tumors of the central nervous system.

Clinicopathological characteristics and treatment of rhabdoid glioblastoma.

Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.

A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system.

An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.

Complete response to steroids in dural inflammatory pseudotumor associated with Still's disease.

Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.

Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.

An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.

A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model.

Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.

Enhanced oncolytic virotherapy through oxidative stress inhibition.

SEER insights.

EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.

Impact of PhD training on scholarship in a neurosurgical career.

Editorial on "heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial".

Methodology and reporting of meta-analyses in the neurosurgical literature.

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody.

Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.

Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells.

EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.

Response.

Worse outcomes for patients undergoing brain tumor and cerebrovascular procedures following the ACGME resident duty-hour restrictions.

Oncolytic polio virotherapy of cancer.

A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma.

Immunological targeting of cytomegalovirus for glioblastoma therapy.

Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.

Antibody-based immunotherapy for malignant glioma.

Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.

Immunotherapy advances for glioblastoma.

Recurrent malignant gliomas.

Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.

Epidermal growth factor receptor and variant III targeted immunotherapy.

Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression.

Severe Adverse Immunologic Reaction in a Patient with Glioblastoma Receiving Autologous Dendritic Cell Vaccines Combined with GM-CSF and Dose-Intensified Temozolomide.

Immunotherapy for primary brain tumors: no longer a matter of privilege.

Defining the Optimal Planning Target Volume in Image-Guided Stereotactic Radiosurgery of Brain Metastases: Results of a Randomized Trial.

Peptide vaccines for the treatment of glioblastoma.

Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma.

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.

Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: Implications for drug development.

Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy.

Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence.